Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy. - Wikidata - wikimedia - TriplyDB

Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy.

Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy.

http://www.wikidata.org/entity/Q37720009

about

Death Receptor 3 Signaling Controls the Balance between Regulatory and Effector Lymphocytes in SAMP1/YitFc Mice with Crohn's Disease-Like Ileitis.

P2860

Q51739535-C389555A-E5AD-4B2B-9C59-49EFEFC4F742

P2860

Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy.

http://www.wikidata.org/entity/Q37720009

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Changes in TL1A levels and ass ...... nesis of diabetic retinopathy.

@en

Changes in TL1A levels and ass ...... nesis of diabetic retinopathy.

@nl

type

label

Changes in TL1A levels and ass ...... nesis of diabetic retinopathy.

@en

Changes in TL1A levels and ass ...... nesis of diabetic retinopathy.

@nl

prefLabel

Changes in TL1A levels and ass ...... nesis of diabetic retinopathy.

@en

Changes in TL1A levels and ass ...... nesis of diabetic retinopathy.

@nl

P1433

Q37720009-DE0F46C0-ED8D-47F8-B18E-F0CF11194EAF

P1476

Q37720009-EE2AEE68-7DE5-4428-9E0C-0520C5CDD667

P2093

Q37720009-06854575-62D3-4FDC-A902-64CAE6A8DCF6

Q37720009-0CDCFE4C-700C-4F8D-8845-936D8051BA53

Q37720009-249EC225-E017-4C76-912A-7CEA2555751D

Q37720009-4653C467-A682-442B-8275-C2F6096D5436

Q37720009-51B21587-D375-434C-B918-5C313524E8E8

Q37720009-9445019C-1C5C-4CD3-9592-84B9CD79D9F3

Q37720009-B9285884-68C7-4CB3-B709-8583188FA241

Q37720009-C7DCE35C-6CF4-406F-995A-E7A35B23AE02

Q37720009-E8E79C76-8995-4678-99FE-32AB637E86DA

Q37720009-F825D06E-00D6-411C-AD47-96F5F5A5BBF7

P2860

Q37720009-0369AB7C-5DCC-475B-B797-2C02D5274F9F

Q37720009-07779C5E-9B3C-4695-8319-BC66DFB6712F

Q37720009-196E058B-B812-4F7A-BB64-6B7BD837D130

Q37720009-355E16FF-61F6-4773-AA5A-7B508E2BAC36

Q37720009-3CE3AC1C-26AA-4EB9-A98F-8851EEC92741

Q37720009-582B22F7-721D-449B-A361-C1E1760F9548

Q37720009-62B32B50-C69B-4D0A-AF72-C535C7D7DA91

Q37720009-6DD855A6-678B-4359-817B-B09F2DA0B057

Q37720009-7391610B-43AF-4547-A7A8-0CC59602C3AF

Q37720009-73F26333-F9FD-49E1-9D29-E3C4B7D8BF8D

P304

Q37720009-AFE9B24F-1D4B-45A8-86F4-3B8E7648B701

P31

Q37720009-EF105E82-CBD7-4964-80D8-B6ED3D70D221

P356

Q37720009-B0C18AAA-1F4E-4592-A860-D1AE1561CFE4

P433

Q37720009-3E64A676-80F4-439F-9482-02A70B42D93F

P478

Q37720009-A3221A6E-EEEC-4AA9-9C87-A8B49161F3F0

P577

Q37720009-8529BDDC-75E2-48C3-8BE6-3FDA5F5E5106

P698

Q37720009-E080A908-DC82-4A47-9C4E-CDD58558B2EB

P921

Q37720009-97C147CA-51CD-484E-82C6-888E54EF94D6

P932

Q37720009-761172B0-57C9-4D88-B709-DB9EC440D4D0

P356

P1433

Molecular Medicine Reports

P1476

Changes in TL1A levels and ass ...... nesis of diabetic retinopathy.

@en

P2093

Cai-Yun You

http://www.w3.org/2001/XMLSchema#string

Chun-Jie Mao

http://www.w3.org/2001/XMLSchema#string

Feng Jiang

http://www.w3.org/2001/XMLSchema#string

Hua Yan

http://www.w3.org/2001/XMLSchema#string

Jin-Guo Yu

http://www.w3.org/2001/XMLSchema#string

Qing-Zhong Chen

http://www.w3.org/2001/XMLSchema#string

Todd A Townsend

http://www.w3.org/2001/XMLSchema#string

Wen-Hui Yang

http://www.w3.org/2001/XMLSchema#string

Zhi-Yong Sun

http://www.w3.org/2001/XMLSchema#string

Zhu-Hong Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo

Pathophysiology of diabetic retinopathy

The pathogenesis of edema in diabetic maculopathy.

Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor.

A novel secreted splice variant of vascular endothelial cell growth inhibitor.

Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy

Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.

VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth.

Diabetic retinopathy and VEGF.

Bevacizumab for the management of diabetic macular edema

P304

573-580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MMR.2016.6048

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28000874

http://www.w3.org/2001/XMLSchema#string

P921

P932

5364842

http://www.w3.org/2001/XMLSchema#string